“DFD-03 (0.1% Tazarotene), Twice-Daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product With Once-Daily Overnight Application”. 2017. SKIN The Journal of Cutaneous Medicine 1 (3.1): s46. https://doi.org/10.25251/skin.1.supp.45.